|
KMID : 1022820150060020029
|
|
Journal of Multiple Sclerosis and Neuroimmunology
2015 Volume.6 No. 2 p.29 ~ p.35
|
|
|
Tolerability of Interferon Beta-1b for Multiple Sclerosis and Clinically Isolated Syndrome in Korea
|
|
Kim Yoo-Hwan
Kim Byung-Jo
Kim Byoung-Joon
Oh Jee-Young
Joo In-Soo
Lim Young-Min
Lee Yoen-Jung
Kim Kwang-Kuk
|
|
|
Abstract
|
|
|
Background: Interferon beta-1b has been used for relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) with excellent safety profiles. Although a recent study suggested no difference in clinical manifestations between Caucasians and Koreans, effective drug dosage and tolerability could be different among patients with different ethnicity. This study was performed to investigate tolerability and any factors affecting tolerability of interferon beta-1b in Korean patients with MS or CIS.
Methods: All patients who have been injecting interferon beta-1b for MS or CIS were recruited from 39 nation-wide university affiliated hospitals in Korea from August 2006 to July 2012. All subjects were asked to report any adverse events (AEs) after injecting interferon beta 1b using a selfquestionnaire.
Results: A total of 355 patients (322 MS and 33 CIS) were enrolled. 96 AEs were reported by 59 patients (16.62%) except injection site reaction. 35 AEs by 23 patients (6.48%) were drug related events listed in drug information. Of 16 serious AEs reported by 9 patients (2.54%), 13 events were related to relapse and the other 3 events were 1 suicide attempt and 2 injection site infection. Any injection site reactions were reported in 38% of patients, but all events were mild. No one discontinued interferon beta-1b during study period.
Conclusions: Compared to previous studies, occurrence rate of AEs by interferon beta-1b in Korean patients with MS showed similar results.
|
|
|
KEYWORD
|
|
|
Interferon beta-1b, Relapsing-remitting multiple sclerosis, Clinically isolated syndrome, Tolerability
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|